ArticleBMC infectious diseases2025
Safety and efficacy of BIC/FIC/TAF in older PLHIV: impact on bone density, renal function, and lipid profiles in a real-world Chinese cohort.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to elucidate the efficacy and safety of treatment using a fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) in older patients with HIV in the real world.
methodsA retrospective study was conducted at our hospital between April 2023 and April 2024, and the efficacy and safety of treatment with fixed-dose BIC/FTC/TAF were assessed in 314 patients aged > 50 years living with HIV, including 35 antiretroviral therapy (ART)-naïve patients and 279 ART-experienced patients.
resultsFixed-dose BIC/FTC/TAF displayed good efficacy among older patients, even in five patients with the M184V mutation site. At the 48-week follow-up, the absolute change of bone mineral density (BMD) was compared with baseline values, with results as follows: 0.8876 ± 0.1193 vs. 0.9321 ± 0.1071 g/cm2 in L1 (p = 0.030), 0.9260 ± 0.1327 vs. 0.9758 ± 0.1208 g/cm2 in L2 (p = 0.029), 0.9559 ± 0.1386 vs. 1.0139 ± 0.1355 g/cm2 in L3 (p = 0.018), and 0.9411 ± 0.1486 vs. 1.0250 ± 0.1709 g/cm2 in L4 (p = 0.003). The BMD values in the left or right hip joint (neck, trochanter, and inside) and renal biomarkers tended to improve. Significantly increased serum creatinine and reduced eGFR levels were also observed (p < 0.001). Changes in lipid panel values from baseline were as follows: 1.86 ± 1.21 mmol/L vs 1.66 ± 1.00 mmol/L for triglycerides (TGs) (p = 0.013) and 1.11 ± 0.30 mmol/L vs 1.15 ± 0.32 mmol/L for high-density lipoprotein (p = 0.018).
conclusionsBIC/FTC/TAF presented optimal antiretroviral efficacy, including in patients with the M184V mutation site, and significantly improved outcomes in BMD in the lumbar spine and serum TG levels, while outcomes in the left or right hip joint, renal biomarkers, and other lipid panels presented improved trends after 48 weeks of treatment and follow-up in this real-world study. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.